1. Signaling Pathways
  2. Apoptosis
  3. Apoptosis
  4. Apoptosis Activator

Apoptosis Activator

Apoptosis Activators (273):

Cat. No. Product Name Effect Purity
  • HY-19543
    Brusatol
    Activator 99.89%
    Brusatol (NSC?172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent. Brusatol increases cellular apoptosis.
  • HY-15578
    McMMAF
    Activator 99.96%
    McMMAF (Maleimidocaproyl monomethylauristatin F) is a maleimido-caproyl linker, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) with the protecting group maleimidocaproyl. McMMAF serves as an active molecule linker for ADC. McMMAF is non-cleavable and must be internalized and degraded within the cell to release cysteine-McMMAF as the active molecule. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth.
  • HY-N0303
    Idebenone
    Activator 99.36%
    Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM). Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Idebenone quickly crosses the blood-brain barrier.
  • HY-12467
    OTS964 hydrochloride
    Activator 99.74%
    OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM. OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM.
  • HY-13024
    Rebastinib
    Activator 99.91%
    Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, VEGFR2/KDR/Flk-1, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
  • HY-110127
    NU9056
    Activator 98.81%
    NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells.
  • HY-15601
    Vesatolimod
    Activator 99.90%
    Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC50 of 291 nM.
  • HY-101981
    Uridine 5'-monophosphate
    Activator 99.89%
    Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
  • HY-W451275
    HG106
    Activator 99.95%
    HG106 is an effective SLC7A11 inhibitor. HG106 mediates apoptosis by increasing oxidative stress and endoplasmic reticulum stress, and it has antitumor activity.
  • HY-70044
    GSK-1070916
    Activator 99.55%
    GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
  • HY-P9958
    Denosumab
    Activator 99.10%
    Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.
  • HY-153811
    IAG933
    Activator 99.81%
    IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD4217-434, with an IC50 value of 9 nM.
  • HY-108521
    HX531
    Activator 99.87%
    HX531 is an effective RXR antagonist with oral activity, with an IC50 of 18 nM, with activity against black melanoma. HC531 can eliminate the anti-apoptotic effects of all-trans-retinoic acid (t-RA) and exerts anti-obesity and anti-diabetic effects through leptin-dependent pathways and the p53-p21Cip1 pathway, resulting in G0/G1 cell cycle arrest.
  • HY-136657
    SC-43
    Activator 99.02%
    SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.
  • HY-18314
    GW 441756
    Activator 99.95%
    GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC50=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth.
  • HY-101923B
    LYN-1604 dihydrochloride
    Activator 99.64%
    LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC).
  • HY-14808
    Adarotene
    Activator 99.18%
    Adarotene is an effective apoptosis inducer, which surprisingly produces DNA damage and exhibites a potent antiproliferative activity on a large panel of human tumor cells.
  • HY-10619A
    Niraparib hydrochloride
    Activator 99.41%
    Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-12044
    Cabozantinib S-malate
    Activator 99.90%
    Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2/KDR/Flk-1, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-107737
    1,2-DLPC
    Activator ≥98.0%
    1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells.